Gates Foundation and CureVac collaborate to accelerate the development of transformative vaccine technology

The Bill & Melinda Gates Foundation and CureVac announced that the foundation has made a commitment to invest $52 million in CureVac, a leading clinical-stage biopharmaceutical company specializing in mRNA-based vaccine technologies. As part of the agreement, the foundation will also provide separate funding for several projects to develop prophylactic vaccines based on CureVac’s proprietary messenger RNA (mRNA) platform. In addition, CureVac’s longstanding investor dievini Hopp BioTech announced a commitment of $24 million of additional equity. CureVac is pioneering the use of natural and chemically unmodified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. CureVac’s novel technology is the broadest and most advanced mRNA therapeutic platform and allows for rapid, low-cost production of multiple drugs and vaccines. Additionally, CureVac’s mRNA vaccines are thermostable, which eliminates the demand for cold-chain storage and infrastructure, a major challenge in...